Merck, Inc.

🇵🇭Philippines

Country: 🇵🇭Philippines

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Phase 3

Recruiting

Conditions: Colorectal Neoplasms

Interventions: Drug: Oxaliplatin
Biological: Pembrolizumab
Drug: Leucovorin
Drug: 5-fluorouracil
Drug: Irinotecan
Biological: Bevacizumab
Biological: Cetuximab

First Posted Date: 2022-02-15

Last Posted Date: 2024-12-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT05239741

Locations: 🇨🇳
The First Affiliated Hospital of Chongqing Medical University ( Site 0051), Chongqing, Chongqing, China
🇨🇳
Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China
🇨🇳
Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011), Beijing, Beijing, China

and more 29 locations

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Biological: Pembrolizumab
Drug: Belzutifan
Drug: Placebo

First Posted Date: 2022-02-15

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1800

Registration Number: NCT05239728

Locations: 🇺🇸
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, United States
🇺🇸
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California, United States
🇺🇸
UT Southwestern Medical Center ( Site 3529), Dallas, Texas, United States

and more 282 locations

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: MK-8189
Drug: Placebo

First Posted Date: 2022-02-07

Last Posted Date: 2023-01-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 29

Registration Number: NCT05227118

Locations: 🇺🇸
CITrials ( Site 0007), Santa Ana, California, United States
🇺🇸
iResearch Atlanta ( Site 0009), Decatur, Georgia, United States
🇺🇸
Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008), Princeton, New Jersey, United States

and more 5 locations

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Phase 3

Active, not recruiting

Conditions: Metastatic Non-Small Cell Lung Cancer

Interventions: Biological: Pembrolizumab/Vibostolimab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel
Drug: Pemetrexed
Biological: Pembrolizumab

First Posted Date: 2022-02-07

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 700

Registration Number: NCT05226598

Locations: 🇪🇸
Hospital Clinico San Carlos-Oncology Department ( Site 1107), Madrid, Spain
🇨🇳
Jilin Cancer Hospital-oncology department ( Site 2603), Changchun, Jilin, China
🇨🇳
Zhejiang Cancer Hospital-Oncology ( Site 2612), Hangzhou, Zhejiang, China

and more 146 locations

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Saline placebo
Biological: Pembrolizumab/Vibostolimab Co-Formulation
Drug: Etoposide
Drug: Cisplatin
Biological: Atezolizumab
Drug: Carboplatin

First Posted Date: 2022-02-04

Last Posted Date: 2024-11-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 460

Registration Number: NCT05224141

Locations: 🇯🇵
National Cancer Center Hospital East ( Site 3002), Kashiwa, Chiba, Japan
🇨🇦
Lakeridge Health ( Site 0102), Oshawa, Ontario, Canada
🇩🇪
LungenClinic Grosshansdorf-Onkologie ( Site 0903), Grosshansdorf, Schleswig-Holstein, Germany

and more 137 locations

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Phase 3

Active, not recruiting

Conditions: Endometrial Neoplasms

Interventions: Biological: pembrolizumab
Drug: carboplatin
Drug: paclitaxel
Drug: docetaxel
Drug: cisplatin

First Posted Date: 2021-12-30

Last Posted Date: 2024-11-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 280

Registration Number: NCT05173987

Locations: 🇺🇸
Northside Hospital ( Site 0017), Atlanta, Georgia, United States
🇺🇸
St. Dominic's Hospital ( Site 0024), Jackson, Mississippi, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026), Hackensack, New Jersey, United States

and more 192 locations

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Phase 3

Completed

Conditions: Pneumococcal Infection

Interventions: Biological: V110
Biological: V114
Biological: mRNA-1273
Biological: Placebo for V110
Biological: Placebo for V114

First Posted Date: 2021-12-15

Last Posted Date: 2024-03-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 850

Registration Number: NCT05158140

Locations: 🇺🇸
Valley Clinical Trials Inc. ( Site 0002), Northridge, California, United States
🇵🇷
CAIMED Center - Ponce School of Medicine ( Site 0103), Ponce, Puerto Rico
🇺🇸
Charlottesville Medical Research Center, LLC ( Site 0008), Charlottesville, Virginia, United States

and more 43 locations

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Phase 2

Active, not recruiting

Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Interventions: Biological: MK-2140 (zilovertamab vedotin)

First Posted Date: 2021-12-03

Last Posted Date: 2024-11-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 140

Registration Number: NCT05144841

Locations: 🇫🇷
Centre Hospitalier de la Côte Basque ( Site 1002), Bayonne, Aquitaine, France
🇸🇪
Skånes Universitetssjukhus Lund ( Site 2100), Lund, Skane Lan, Sweden
🇹🇷
Ankara University Hospital Cebeci-hematology ( Site 2300), Ankara, Turkey

and more 68 locations

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Phase 2

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
DLBCL

Interventions: Biological: Zilovertamab vedotin
Biological: Rituximab
Drug: Gemcitabine
Drug: Bendamustine
Drug: Oxaliplatin

First Posted Date: 2021-12-01

Last Posted Date: 2024-12-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 290

Registration Number: NCT05139017

Locations: 🇦🇺
Grampians Health ( Site 1802), Ballarat, Victoria, Australia
🇨🇳
The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan, China
🇨🇷
CIMCA ( Site 2501), San Jose, Costa Rica

and more 55 locations

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

Phase 1

Completed

Conditions: Cognitive Impairment Associated With Schizophrenia

Interventions: Drug: Nicotine patch
Drug: MK-4334
Drug: Placebo patch
Drug: Placebo capsule

First Posted Date: 2021-11-29

Last Posted Date: 2024-11-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 38

Registration Number: NCT05136690

Locations: 🇺🇸
Collaborative Neuroscience Research, LLC ( Site 0002), Long Beach, California, United States
🇺🇸
Hassman Research Institute Marlton Site ( Site 0001), Marlton, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy